Actively Recruiting

Age: 18Years +
FEMALE
Healthy Volunteers
NCT06981481

Post-marketing Clinical Monitoring of Safety and Performance of Breast Tissue Expander for Breast Reconstruction

Led by Silimed Industria de Implantes Ltda · Updated on 2026-03-13

152

Participants Needed

3

Research Sites

120 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The study investigates the safety and performance of Silimed® brand breast tissue expander in women born with indication for breast reconstruction. The safety of the breast tissue expander will be evaluated by estimating known and unexpected adverse event rates through patient reports of adverse events after implantation. The performance of using Silimed® brand breast tissue expander will be evaluated by evaluating the assessment of tissue quality and satisfaction by the evaluating physician after implantation.

CONDITIONS

Official Title

Post-marketing Clinical Monitoring of Safety and Performance of Breast Tissue Expander for Breast Reconstruction

Who Can Participate

Age: 18Years +
FEMALE
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Provide written informed consent
  • Female sex at birth
  • Be 18 years of age or older
  • Have an indication for reconstruction with breast expander and breast implant(s)
  • Plan to receive an expander and implant with textured surface from the Silimed4 brand
  • Ability to comply with the protocol throughout the follow-up period
Not Eligible

You will not qualify if you...

  • Breast augmentation without reconstruction in at least one breast
  • Untreated or currently treated neoplasia of any type except breast neoplasia, or requiring surgical removal at implantation time
  • Pregnancy or breastfeeding at the time of implantation
  • Smoking, uncontrolled diabetes, obesity grade 2 or higher, and ASA III/IV
  • Active infection not treated or being treated at any site at implantation time
  • History of adverse reactions or intolerance to silicone prior to implantation
  • Active immune diseases affecting connective tissue (e.g., lupus erythematosus, discoid lupus, scleroderma) at implantation
  • Use of illicit drugs or medications increasing risk of immediate post-surgical complications
  • High surgical risk or immediate post-surgery complications estimated before implantation
  • Tissue characteristics clinically inconsistent with successful implantation (e.g., excessive fibrosis, compromised vascularization)
  • Participation in another clinical study within 6 months before expander placement unless deemed acceptable by researcher
  • Previous treatment with radiotherapy
  • Any condition preventing informed consent, making participation unsafe, compromising protocol adherence, complicating data interpretation, or interfering with study objectives based on researcher opinion

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 3 locations

1

Hospital de câncer HCIII (INCA)

Rio de Janeiro, Rio de Janeiro, Brazil

Actively Recruiting

2

Fundação do ABC - Centro universitário FMABC

Santo André, São Paulo, Brazil

Not Yet Recruiting

3

Irmandade Santa Casa de Misericórdia de São Paulo

São Paulo, São Paulo, Brazil, 01221-020

Actively Recruiting

Loading map...

Research Team

R

Renata R M Figueira

CONTACT

L

Ludmila C Donato

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here